Tempus AI, Inc. (NASDAQ:TEM – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the ten analysts that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $45.56.
Several equities research analysts have weighed in on TEM shares. Needham & Company LLC reissued a “buy” rating and issued a $47.00 price target on shares of Tempus AI in a report on Wednesday, August 7th. Bank of America assumed coverage on Tempus AI in a research note on Tuesday, July 9th. They issued a “buy” rating and a $41.00 target price for the company. JPMorgan Chase & Co. lifted their price target on Tempus AI from $42.00 to $47.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th. TD Cowen assumed coverage on Tempus AI in a report on Tuesday, July 9th. They issued a “buy” rating and a $50.00 price objective on the stock. Finally, Longbow Research started coverage on Tempus AI in a report on Tuesday, July 9th. They set a “buy” rating and a $48.00 target price for the company.
Read Our Latest Stock Report on TEM
Institutional Investors Weigh In On Tempus AI
Tempus AI Stock Performance
Shares of TEM stock opened at $54.43 on Friday. The stock has a 50-day moving average of $48.37. Tempus AI has a one year low of $22.89 and a one year high of $77.00.
Tempus AI (NASDAQ:TEM – Get Free Report) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($6.77) earnings per share for the quarter, missing the consensus estimate of ($4.41) by ($2.36). The firm had revenue of $165.97 million for the quarter, compared to analysts’ expectations of $159.10 million. On average, equities analysts forecast that Tempus AI will post -6.51 EPS for the current fiscal year.
Tempus AI Company Profile
Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.
See Also
- Five stocks we like better than Tempus AI
- The 3 Best Fintech Stocks to Buy Now
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- Airline Stocks – Top Airline Stocks to Buy Now
- MarketBeat Week in Review – 9/16 – 9/20
- What Do S&P 500 Stocks Tell Investors About the Market?
- Don’t Miss These 3 Retail Stocks for Fall Gains
Receive News & Ratings for Tempus AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempus AI and related companies with MarketBeat.com's FREE daily email newsletter.